Novavax starts human testing of Ebola vaccine
This article was originally published in Scrip
Executive Summary
Novavax revealed on 12 February that it has started testing its Ebola glycoprotein (GP) recombinant nanoparticle vaccine candidate in healthy human volunteers to determine if it is safe.